Streetbeat News

MIRO

Miromatrix Medical Inc

Employees

Industry

Biological Product (except Diagnostic) Manufacturing

miromatrix medical inc. is a life science company that has a novel and proprietary technology to remove cells from, or decellularize, organs and tissues from animal and human sources, facilitating the creation of numerous products, including the potential of fully biological transplantable human organs.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

United Therapeutics has agreed to acquire Miromatrix Medical for $3.25 per share in cash. This has led to a surge in Miromatrix's share price.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 10:56 am

United Therapeutics has agreed to acquire Miromatrix Medical for $3.25 per share in cash, totaling approximately $91 million. An additional $1.75 per share in cash will be paid upon the achievement of a clinical development milestone.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 10:03 am

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Novo Integrated Sciences (NVOS), Tivic Health Systems (TIVC), Navidea Biopharmaceutical (NAVB), Miromatrix Medical (MIRO), Catalyst Biosciences (CBIO), and Star Equity Hldgs (STRR). Losers included Impel Pharmaceuticals (IMPL), RVL Pharmaceuticals (RVLP), Mallinckrodt (MNK), Rockwell Medical (RMTI), G Medical Innovations (GMVD), and PAVmed (PAVM).

Portfolio Pulse from Benzinga Insights

August 16, 2023 | 5:31 pm

Miromatrix Medical (NASDAQ:MIRO) reported Q2 losses of $(0.24) per share, beating the analyst consensus estimate of $(0.32) by 25 percent. This is a 40 percent improvement over the same period last year. However, the company's quarterly sales of $8.52 thousand missed the analyst consensus estimate of $10.00 thousand by 14.83 percent, despite a 115.51 percent increase over last year.

Portfolio Pulse from vinayak@benzinga.com

August 14, 2023 | 8:26 pm

Miromatrix Medical (NASDAQ:MIRO) is set to release its quarterly earnings report on Monday, 2023-08-14, with an estimated EPS of $-0.32. The company's past performance shows a trend of missing EPS estimates, which has led to a drop in share prices. Over the last 52-week period, shares are down 53.54%.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 4:01 pm

Motorcar Parts of America shares rose 13.5% after reporting Q4 profit. Other stocks with significant gains include First Wave BioPharma, IperionX, Ideanomics, and Cepton. Losers include Auddia, Advanced Health Intelligence, Bonso Electronics, and Jin Medical International.

Portfolio Pulse from Lisa Levin

June 13, 2023 | 4:47 pm

American Software shares dropped 20.8% despite better-than-expected Q4 earnings, as sales missed estimates and FY24 revenue guidance was between $120 million and $126 million. Other stocks experienced significant price movements during Friday's mid-day session.

Portfolio Pulse from Lisa Levin

June 09, 2023 | 4:49 pm

Miromatrix Medical Inc. (NASDAQ:MIRO) announced that CEO Jeff Ross, Ph.D., will resume leadership of the R&D organization after the departure of John Barry as Vice President of R&D. The transition will not impact the company's timelines and milestones, including the submission of a response to the FDA's clinical hold letter in H2 2023.

Portfolio Pulse from Happy Mohamed

June 01, 2023 | 8:04 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.